Hyderabad: Bharat Biotech’s Covaxin vaccine gets WHO approval for emergency use
The World Health Organisation (WHO) on Wednesday granted approval for Emergency Use Listing (EUL) to Bharat Biotech’s Covaxin vaccine for COVID-19.
At G-20 summit, Prime Minister Narendra Modi pushed for WHO nod for Covaxin, saying India to produce five billion Covid vaccine doses by 2022.
The Technical Advisory Group of WHO, which met today, has recommended the Emergency Use Listing status for Covaxin. The World Health Organisation’s panel had last week sought additional clarifications from the Hyderabad-based firm.
Covaxin vaccine was also reviewed by WHO’s strategic advisory group of experts on immunization (SAGE) and recommonded use of this vaccine in two doses, with a dose of interval of four weeks, in all age groups of 18 and above.
WHO in a series of tweets said, Covaxin vaccine adds to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19.
WHO said, Covaxin EUL expands the availability of the most effective medical tools to end COVID 19. WHO also allowed countries to expedite their own regulatory approval to import and administer COVID-19vaccines.
WHO also stressed that the aim is to make medicines, vaccines and diagnostics available as rapidly as possible while adhering to stringent criteria of safety, efficacy and quality.
Covaxin is one of the six vaccines that have received emergency use authorisation from Drugs Controller General of India and is being used in the nationwide inoculation programme, along with Covishield and Sputnik V.
WHO South East Asia Regional Director Dr Poonam Khetrapal Singh in a tweet congratulated India for Covaxin’s listing for emergency use.